CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting

Tyrosine kinase inhibitors (TKIs) are highly effective for the treatment of chronic myeloid leukemia (CML), but very few patients are cured. The major drawbacks regarding TKIs are their low efficacy in eradicating the leukemic stem cells responsible for disease maintenance and relapse upon drug cess...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Niklas Landberg, Sofia von Palffy, Maria Askmyr, Henrik Lilljebjörn, Carl Sandén, Marianne Rissler, Satu Mustjoki, Henrik Hjorth-Hansen, Johan Richter, Helena Ågerstam, Marcus Järås, Thoas Fioretos
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2018-03-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/8382
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!